精华制药(002349) - 2017 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2017 was CNY 303,374,731.47, representing a 38.98% increase compared to CNY 218,285,420.51 in the same period last year[8] - Net profit attributable to shareholders decreased by 23.57% to CNY 31,951,248.03 from CNY 41,806,897.38 year-on-year[8] - Basic and diluted earnings per share both fell by 23.69% to CNY 0.0380 from CNY 0.0498 in the same quarter last year[8] - The company expects net profit attributable to shareholders for the first half of 2017 to range from ¥8,083,000 to ¥9,700,000, representing a growth of 0% to 20%[19] Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -58,685,656.16, a decline of 151.55% compared to CNY 113,831,448.18 in the previous year[8] - Cash and cash equivalents decreased by 32.92% to ¥259,055,649.73 due to cash dividends distribution and increased prepayments for materials[15] - Total assets increased by 3.92% to CNY 2,629,745,298.04 from CNY 2,530,494,973.86 at the end of the previous year[8] - Net assets attributable to shareholders decreased by 0.62% to CNY 2,135,691,360.12 from CNY 2,149,084,263.90 at the end of the previous year[8] Shareholder Information - The total number of shareholders at the end of the reporting period was 42,167[11] - The largest shareholder, Nantong Industrial Holdings Group Co., Ltd., held 34.09% of the shares, amounting to 37,956,480 shares[11] Operational Metrics - Operating revenue rose by 38.98% to ¥303,374,731.47, driven by increased sales from subsidiaries[16] - Operating costs increased by 39.47% to ¥159,263,789.19, reflecting the rise in sales revenue[16] - Accounts receivable increased by 46.04% to ¥204,647,596.39, attributed to significant sales revenue growth[15] Expenses and Provisions - Development expenditures surged by 68.68% to ¥46,678,401.05, primarily due to increased spending on R&D projects[15] - The company reported a significant increase in financial expenses by 109.42% to ¥788,564.19, due to reduced interest income[16] - The company reported a provision for impairment of 39,145,352.99 yuan during the period[22] Other Financial Information - Short-term borrowings doubled to ¥40,000,000.00, indicating increased bank loans during the reporting period[15] - Other receivables increased by 91.51% to ¥20,198,194.87, mainly due to higher payments made with invoices not yet received[15] - Deferred income rose by 116.36% to ¥9,122,165.98, attributed to special funds received by subsidiaries[15] Compliance and Governance - There were no instances of non-compliance with external guarantees during the reporting period[23] - The company did not have any non-operating fund occupation by controlling shareholders or related parties during the reporting period[24] - The company conducted an on-site investigation on February 16, 2017, as part of its investor relations activities[25] Return on Equity - The weighted average return on equity was 1.48%, down from 2.03% in the same period last year, a decrease of 0.55%[8] Non-Recurring Items - The company reported non-recurring gains and losses totaling CNY 929,881.04 for the period[9]